IN2014KN02952A - - Google Patents
Info
- Publication number
- IN2014KN02952A IN2014KN02952A IN2952KON2014A IN2014KN02952A IN 2014KN02952 A IN2014KN02952 A IN 2014KN02952A IN 2952KON2014 A IN2952KON2014 A IN 2952KON2014A IN 2014KN02952 A IN2014KN02952 A IN 2014KN02952A
- Authority
- IN
- India
- Prior art keywords
- nogo
- als
- prophylaxis
- exclusively
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668134P | 2012-07-05 | 2012-07-05 | |
| PCT/EP2013/064063 WO2014006105A1 (en) | 2012-07-05 | 2013-07-03 | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02952A true IN2014KN02952A (es) | 2015-05-08 |
Family
ID=48741180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2952KON2014 IN2014KN02952A (es) | 2012-07-05 | 2013-07-03 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2870177A1 (es) |
| JP (1) | JP2015521992A (es) |
| KR (1) | KR20150036398A (es) |
| CN (1) | CN104395343A (es) |
| AU (1) | AU2013285493A1 (es) |
| BR (1) | BR112014032987A2 (es) |
| CA (1) | CA2876284A1 (es) |
| IN (1) | IN2014KN02952A (es) |
| RU (1) | RU2014150265A (es) |
| WO (1) | WO2014006105A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102279751B1 (ko) * | 2019-06-28 | 2021-07-21 | 경북대학교 산학협력단 | 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법 |
| KR102409771B1 (ko) * | 2020-06-17 | 2022-06-16 | 경북대학교 산학협력단 | Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| DE10336350B4 (de) | 2003-08-08 | 2007-10-31 | Westfalia Separator Ag | Vollmantel-Schneckenzentrifuge, mit Schälscheibe |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| WO2005061545A2 (en) | 2003-12-22 | 2005-07-07 | Glaxo Group Limited | Nogoa antibodies for the treatment of alzheimer disease |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| DK2207808T3 (da) | 2007-11-02 | 2013-08-05 | Novartis Ag | Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse |
| CA2730473A1 (en) | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
-
2013
- 2013-07-03 CN CN201380035806.8A patent/CN104395343A/zh active Pending
- 2013-07-03 RU RU2014150265A patent/RU2014150265A/ru not_active Application Discontinuation
- 2013-07-03 KR KR20157003097A patent/KR20150036398A/ko not_active Application Discontinuation
- 2013-07-03 WO PCT/EP2013/064063 patent/WO2014006105A1/en active Application Filing
- 2013-07-03 EP EP13732986.8A patent/EP2870177A1/en not_active Withdrawn
- 2013-07-03 JP JP2015519214A patent/JP2015521992A/ja not_active Withdrawn
- 2013-07-03 BR BR112014032987A patent/BR112014032987A2/pt not_active IP Right Cessation
- 2013-07-03 AU AU2013285493A patent/AU2013285493A1/en not_active Abandoned
- 2013-07-03 IN IN2952KON2014 patent/IN2014KN02952A/en unknown
- 2013-07-03 CA CA2876284A patent/CA2876284A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014032987A2 (pt) | 2017-06-27 |
| CA2876284A1 (en) | 2014-01-09 |
| WO2014006105A1 (en) | 2014-01-09 |
| CN104395343A (zh) | 2015-03-04 |
| EP2870177A1 (en) | 2015-05-13 |
| AU2013285493A1 (en) | 2015-01-22 |
| KR20150036398A (ko) | 2015-04-07 |
| RU2014150265A (ru) | 2016-08-27 |
| JP2015521992A (ja) | 2015-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011905A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| MX2016017355A (es) | Lipido que comprende acido docosapentaenoico. | |
| MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
| MX2015015148A (es) | Proceso para la preparacion de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos en una cascada de reactores. | |
| MX2015006337A (es) | Metodos y composiciones para tratar enfermedades neurodegenerativas. | |
| NZ730092A (en) | Use of cysteamine in treating infections caused by yeasts/moulds | |
| PH12016500903A1 (en) | Novel methods for treating neurodegenerative diseases | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| WO2014147503A3 (en) | Anti-bag3 antibodies for therapeutic use | |
| PH12016501183A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| EP2919816A4 (en) | COMBINATION TREATMENT FOR AMYOTROPHE LATERAL SCLEROSIS (ALS) | |
| IN2013MU01113A (es) | ||
| IN2014DN10209A (es) | ||
| PH12016501182A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| PH12016501184A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| IN2014KN02952A (es) | ||
| MX2013002111A (es) | Metodos y composiciones para el tratamiento de metastasis del cancer. | |
| AU2012240388A8 (en) | Treatment regimens | |
| IN2014DN07989A (es) | ||
| MY164592A (en) | Method for emulsion treatment | |
| UA114811C2 (uk) | Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу | |
| PH12016500541A1 (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis | |
| MX2015009161A (es) | Polioles, su preparación y su uso. | |
| IN2013MU03768A (es) | ||
| GB201114923D0 (en) | Immunogenic proteins and compositions |